Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

The Duffy Antigen Receptor for Chemokines DARC/ACKR1.

Horuk R.

Front Immunol. 2015 Jun 5;6:279. doi: 10.3389/fimmu.2015.00279. eCollection 2015. Review. No abstract available.

2.

CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK-779.

Nedjai B, Viney JM, Li H, Hull C, Anderson CA, Horie T, Horuk R, Vaidehi N, Pease JE.

Br J Pharmacol. 2015 Apr;172(7):1822-33. doi: 10.1111/bph.13027. Epub 2015 Feb 10.

3.

Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4.

Pease JE, Horuk R.

Expert Opin Drug Discov. 2014 May;9(5):467-83. doi: 10.1517/17460441.2014.897324. Epub 2014 Mar 18. Review.

PMID:
24641500
4.

International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A.

Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467.

5.

Cell-autonomous regulation of neutrophil migration by the D6 chemokine decoy receptor.

Rot A, McKimmie C, Burt CL, Pallas KJ, Jamieson T, Pruenster M, Horuk R, Nibbs RJB, Graham GJ.

J Immunol. 2013 Jun 15;190(12):6450-6456. doi: 10.4049/jimmunol.1201429. Epub 2013 May 13.

6.

Chemokine receptor antagonists.

Pease J, Horuk R.

J Med Chem. 2012 Nov 26;55(22):9363-92. doi: 10.1021/jm300682j. Epub 2012 Sep 24. No abstract available.

PMID:
22931505
7.

Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3.

Nedjai B, Li H, Stroke IL, Wise EL, Webb ML, Merritt JR, Henderson I, Klon AE, Cole AG, Horuk R, Vaidehi N, Pease JE.

Br J Pharmacol. 2012 Jun;166(3):912-23. doi: 10.1111/j.1476-5381.2011.01660.x.

8.

Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis.

Lebre MC, Vergunst CE, Choi IY, Aarrass S, Oliveira AS, Wyant T, Horuk R, Reedquist KA, Tak PP.

PLoS One. 2011;6(7):e21772. doi: 10.1371/journal.pone.0021772. Epub 2011 Jul 1.

9.

4-Azetidinyl-1-heteroatom linked cyclohexane antagonists of CCR2: patent evaluation.

Horuk R, Guilford W.

Expert Opin Ther Pat. 2011 Aug;21(8):1275-80. doi: 10.1517/13543776.2011.584872. Epub 2011 May 10. Review.

PMID:
21554155
10.

The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis.

Yang X, Walton W, Cook DN, Hua X, Tilley S, Haskell CA, Horuk R, Blackstock AW, Kirby SL.

Am J Respir Cell Mol Biol. 2011 Jul;45(1):127-35. doi: 10.1165/rcmb.2010-0265OC. Epub 2010 Sep 24.

11.

Small molecule antagonists of chemokine receptors--is promiscuity a virtue?

Pease JE, Horuk R.

Curr Top Med Chem. 2010;10(13):1351-8. Review.

PMID:
20536423
12.

Duffy antigen inhibitors: useful therapeutics for malaria?

Handel TM, Horuk R.

Trends Parasitol. 2010 Jul;26(7):329-33. doi: 10.1016/j.pt.2010.03.010. Epub 2010 Apr 9.

PMID:
20382562
13.

In vitro screening for chemokine antagonists.

Ribeiro S, Horuk R.

Expert Opin Drug Discov. 2009 Oct;4(10):1017-34. doi: 10.1517/17460440902956628. Epub 2009 Sep 19.

PMID:
23480395
14.

Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis.

Blasko E, Haskell CA, Leung S, Gualtieri G, Halks-Miller M, Mahmoudi M, Dennis MK, Prossnitz ER, Karpus WJ, Horuk R.

J Neuroimmunol. 2009 Sep 29;214(1-2):67-77. doi: 10.1016/j.jneuroim.2009.06.023. Epub 2009 Aug 6.

15.

Drug discovery targeting the chemokine system--where are we?

Horuk R, Proudfoot AE.

Front Biosci (Elite Ed). 2009 Jun 1;1:209-19. Review.

PMID:
19482638
16.

Chapter 9 the duffy antigen receptor for chemokines.

Rot A, Horuk R.

Methods Enzymol. 2009;461:191-206. doi: 10.1016/S0076-6879(09)05409-3.

PMID:
19480920
17.

Modeling small molecule-compound binding to G-protein-coupled receptors.

Vaidehi N, Pease JE, Horuk R.

Methods Enzymol. 2009;460:263-88. doi: 10.1016/S0076-6879(09)05213-6.

PMID:
19446730
18.

Chemokine receptor antagonists: part 2.

Pease JE, Horuk R.

Expert Opin Ther Pat. 2009 Feb;19(2):199-221. doi: 10.1517/13543770802641353. Review.

PMID:
19441918
19.

Chemokine receptor antagonists: Part 1.

Pease JE, Horuk R.

Expert Opin Ther Pat. 2009 Jan;19(1):39-58. doi: 10.1517/13543770802641346. Review.

PMID:
19441897
20.

Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5.

Hall SE, Mao A, Nicolaidou V, Finelli M, Wise EL, Nedjai B, Kanjanapangka J, Harirchian P, Chen D, Selchau V, Ribeiro S, Schyler S, Pease JE, Horuk R, Vaidehi N.

Mol Pharmacol. 2009 Jun;75(6):1325-36. doi: 10.1124/mol.108.053470. Epub 2009 Mar 18.

PMID:
19297521
21.

Expression, purification and in vitro functional reconstitution of the chemokine receptor CCR1.

Allen SJ, Ribeiro S, Horuk R, Handel TM.

Protein Expr Purif. 2009 Jul;66(1):73-81. doi: 10.1016/j.pep.2009.03.001. Epub 2009 Mar 9.

22.

Promiscuous drugs as therapeutics for chemokine receptors.

Horuk R.

Expert Rev Mol Med. 2009 Jan 6;11:e1. doi: 10.1017/S1462399409000921. Review.

PMID:
19123963
23.

Chemokine receptor antagonists: overcoming developmental hurdles.

Horuk R.

Nat Rev Drug Discov. 2009 Jan;8(1):23-33. doi: 10.1038/nrd2734. Epub 2008 Dec 12. Review.

PMID:
19079127
24.

Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury.

Furuichi K, Gao JL, Horuk R, Wada T, Kaneko S, Murphy PM.

J Immunol. 2008 Dec 15;181(12):8670-6.

25.

CCR5 deficiency aggravates crescentic glomerulonephritis in mice.

Turner JE, Paust HJ, Steinmetz OM, Peters A, Meyer-Schwesinger C, Heymann F, Helmchen U, Fehr S, Horuk R, Wenzel U, Kurts C, Mittrücker HW, Stahl RA, Panzer U.

J Immunol. 2008 Nov 1;181(9):6546-56.

26.

Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal mice.

Lange-Sperandio B, Trautmann A, Eickelberg O, Jayachandran A, Oberle S, Schmidutz F, Rodenbeck B, Hömme M, Horuk R, Schaefer F.

Am J Pathol. 2007 Sep;171(3):861-71. Epub 2007 Aug 3.

27.

Chemokines.

Horuk R.

ScientificWorldJournal. 2007 Feb 19;7:224-32. Review.

29.

Treatment with BX471, a CC chemokine receptor 1 antagonist, attenuates systemic inflammatory response during sepsis.

He M, Horuk R, Moochhala SM, Bhatia M.

Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1173-80. Epub 2007 Jan 18. Erratum in: Am J Physiol Gastrointest Liver Physiol. 2012 Jan;302(1):G194.

30.

Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage.

Bedke J, Kiss E, Schaefer L, Behnes CL, Bonrouhi M, Gretz N, Horuk R, Diedrichs-Moehring M, Wildner G, Nelson PJ, Gröne HJ.

Am J Transplant. 2007 Mar;7(3):527-37. Epub 2007 Jan 4.

31.

Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.

Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K, Van Valckenborgh E, Van Riet I, Van Camp B, Horuk R, Croucher P, Vanderkerken K.

Clin Exp Metastasis. 2006;23(5-6):291-300. Epub 2006 Nov 3.

PMID:
17086356
32.

Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation.

Vaidehi N, Schlyer S, Trabanino RJ, Floriano WB, Abrol R, Sharma S, Kochanny M, Koovakat S, Dunning L, Liang M, Fox JM, de Mendonça FL, Pease JE, Goddard WA 3rd, Horuk R.

J Biol Chem. 2006 Sep 15;281(37):27613-20. Epub 2006 Jul 12.

33.

I want a new drug: G-protein-coupled receptors in drug development.

Schlyer S, Horuk R.

Drug Discov Today. 2006 Jun;11(11-12):481-93. Review.

PMID:
16713899
34.

A CCR1 antagonist prevents the development of experimental autoimmune myocarditis in association with T cell inactivation.

Futamatsu H, Suzuki J, Koga N, Adachi S, Kosuge H, Maejima Y, Haga T, Hirao K, Horuk R, Isobe M.

J Mol Cell Cardiol. 2006 Jun;40(6):853-61. Epub 2006 May 12.

PMID:
16698032
35.

Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8.

Haskell CA, Horuk R, Liang M, Rosser M, Dunning L, Islam I, Kremer L, Gutiérrez J, Marquez G, Martinez-A C, Biscone MJ, Doms RW, Ribeiro S.

Mol Pharmacol. 2006 Jan;69(1):309-16. Epub 2005 Oct 12.

PMID:
16221874
36.

BX471: a CCR1 antagonist with anti-inflammatory activity in man.

Horuk R.

Mini Rev Med Chem. 2005 Sep;5(9):791-804. Review.

PMID:
16178722
37.
38.

CCR1 antagonists in clinical development.

Pease JE, Horuk R.

Expert Opin Investig Drugs. 2005 Jul;14(7):785-96. Review.

PMID:
16022568
39.

The clinical potential of chemokine receptor antagonists.

Ribeiro S, Horuk R.

Pharmacol Ther. 2005 Jul;107(1):44-58. Review.

PMID:
15894378
40.

Differential inhibition of inducible T cell cytokine secretion by potent iron chelators.

Leung S, Holbrook A, King B, Lu HT, Evans V, Miyamoto N, Mallari C, Harvey S, Davey D, Ho E, Li WW, Parkinson J, Horuk R, Jaroch S, Berger M, Skuballa W, West C, Pulk R, Phillips G, Bryant J, Subramanyam B, Schaefer C, Salamon H, Lyons E, Schilling D, Seidel H, Kraetzschmar J, Snider M, Perez D.

J Biomol Screen. 2005 Mar;10(2):157-67.

PMID:
15799959
41.

MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.

Oba Y, Lee JW, Ehrlich LA, Chung HY, Jelinek DF, Callander NS, Horuk R, Choi SJ, Roodman GD.

Exp Hematol. 2005 Mar;33(3):272-8.

PMID:
15730850
42.

Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease.

Ninichuk V, Gross O, Reichel C, Khandoga A, Pawar RD, Ciubar R, Segerer S, Belemezova E, Radomska E, Luckow B, Perez de Lema G, Murphy PM, Gao JL, Henger A, Kretzler M, Horuk R, Weber M, Krombach F, Schlöndorff D, Anders HJ.

J Am Soc Nephrol. 2005 Apr;16(4):977-85. Epub 2005 Feb 16.

43.

CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome.

Vielhauer V, Berning E, Eis V, Kretzler M, Segerer S, Strutz F, Horuk R, Gröne HJ, Schlöndorff D, Anders HJ.

Kidney Int. 2004 Dec;66(6):2264-78.

44.

Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice.

Anders HJ, Belemezova E, Eis V, Segerer S, Vielhauer V, Perez de Lema G, Kretzler M, Cohen CD, Frink M, Horuk R, Hudkins KL, Alpers CE, Mampaso F, Schlöndorff D.

J Am Soc Nephrol. 2004 Jun;15(6):1504-13. Erratum in: J Am Soc Nephrol. 2004 Aug;15(8):following table of contents.

45.

Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction.

Eis V, Luckow B, Vielhauer V, Siveke JT, Linde Y, Segerer S, Perez De Lema G, Cohen CD, Kretzler M, Mack M, Horuk R, Murphy PM, Gao JL, Hudkins KL, Alpers CE, Gröne HJ, Schlöndorff D, Anders HJ.

J Am Soc Nephrol. 2004 Feb;15(2):337-47.

46.

Preliminary observations on CC chemokine receptor expression by mononuclear phagocytes in multiple sclerosis lesions: effect of lesion heterogeneity.

Mahad D, Trebst C, Staugaitis SM, Kivisäkk P, Tucky B, Wei T, Horuk R, Ransohoff RM.

Ernst Schering Res Found Workshop. 2004;(45):59-68. No abstract available.

PMID:
14699794
47.

CCR1 is an early and specific marker of Alzheimer's disease.

Halks-Miller M, Schroeder ML, Haroutunian V, Moenning U, Rossi M, Achim C, Purohit D, Mahmoudi M, Horuk R.

Ann Neurol. 2003 Nov;54(5):638-46.

PMID:
14595653
48.

Chemokine receptor antagonists from discovery to the clinic.

Horuk R.

Ernst Schering Res Found Workshop. 2004;(44):169-90. Review. No abstract available.

PMID:
14579780
49.
50.

Structure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1.

Onuffer J, McCarrick MA, Dunning L, Liang M, Rosser M, Wei GP, Ng H, Horuk R.

J Immunol. 2003 Feb 15;170(4):1910-6.

Supplemental Content

Support Center